An Open Label Extension Study in Subjects With Fragile X Syndrome
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study will enroll subjects who have completed Protocols 209FX301, 209FX302, or are
currently participating in Protocol 2202 into a long-term study in which all subjects will
receive active drug (arbaclofen).